Revision as of 02:47, 25 July 2023

0 regimens on this page 0 variants on this page

Guidelines

NCCN does not have guidelines at this granular level; please go to the Central Nervous System Cancers category page.

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Ji et al. 2015 (SWOG S9005)	1992-1998	Phase 3 (C)	Mifepristone	Did not meet primary endpoint of FFS

No active antineoplastic treatment.

SWOG S9005: Ji Y, Rankin C, Grunberg S, Sherrod AE, Ahmadi J, Townsend JJ, Feun LG, Fredericks RK, Russell CA, Kabbinavar FF, Stelzer KJ, Schott A, Verschraegen C. Double-blind phase III randomized trial of the antiprogestin agent mifepristone in the treatment of unresectable meningioma: SWOG S9005. J Clin Oncol. 2015 Dec 1;33(34):4093-8. Epub 2015 Nov 2. link to original article link to PMC article PubMed NCT03015701

@@ Line 3: / Line 3: @@
 [[#top|Back to Top]]
 </div>
-{| class="wikitable" style="text-align:center; width:50%;"
+{{#lst:Section editor transclusions|neuro}}
-!colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c"|'''Section editor'''
-|-
-|style="background-color:#F0F0F0"|[[File:SeemaNagpal.jpg|frameless|upright=0.3|center]]
-|<big>[[User:Seemanagpal|Seema Nagpal, MD]]<br>Stanford University<br>Palo Alto, CA</big>
-|-
-|}
 {| class="wikitable" style="float:right; margin-right: 5px;"
 |-